Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2011
  • Online publication date: December 2011

Chapter 19 - Fertility considerations and methods of fertility preservation in patients undergoing treatment for cancer

from Section 3 - Management of maternal complications during treatment
Export citation
Summary
This chapter describes the diagnosis, treatment, prognosis, and lactation for ovarian cancer in pregnancy. Various sonographic scoring systems of the adnexal mass may include features that have been associated with ovarian malignancies, such as bilaterality, heterogeneous solid component, papillary structure, septations, size >7 cm, low-resistance blood flow, and ascites. Improvement in Doppler ultrasound technology for evaluation of tumor vascularity has been used lately as a predictor of malignancy. Magnetic resonance imaging (MRI) may be used as an additional diagnostic imaging tool in more complex conditions, such as displacement of the ovaries up into the abdomen when the pregnant uterus is growing, or in metastatic disease, or in other diagnostic uncertainty. Most patients with ovarian cancer diagnosed during pregnancy have disease confined to the pelvis or abdomen. Paclitaxel-carboplatin chemotherapy until fetal maturity is the regimen of choice in ovarian cancer.

Keywords:

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Cancer in Pregnancy and Lactation
  • Online ISBN: 9780511794995
  • Book DOI: https://doi.org/10.1017/CBO9780511794995
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×

References

1. BroughamMF, WallaceWH. Subfertility in children and young people treated for solid and haematological malignancies. Br J Haematol. 2005;131:143–55.
2. NakayamaK, MilbourneA, SchoverLR, ChamplinRE, UenoNT. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nat Clin Pract Oncol. 2008;5:78–89.
3. JerussJS, WoodruffTK. Preservation of Fertility in Patients with Cancer. N Engl J Med. 2009;360:902–11.
4. van CasterenNJ, BoellaardWP, RomijnJC, DohleGR. Gonadal dysfunction in male cancer patients before cytotoxic treatment. Int J Androl. 2010;33:73–9.
5. HowellSJ, ShaletSM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Monogr Inst. 2005;34:12–7.
6. LampeH, HorwichA, NormanA, NichollsJ, DearnaleyDP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol. 1997;15:239–45.
7. RuefferU, BreuerK, JostingA, et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol. 2001;12:1307–11.
8. KiserudCE, FossaA, BjøroT, HolteH, CvancarovaM, FossaSD. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer. 2009;100:455–63.
9. De BruinML, HuisbrinkJ, HauptmannM, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood. 2008;111:101–8.
10. ByrneJ, FearsTR, MillsJL, et al. Fertility of long-term male survivors of acute lymphoblastic leukemia diagnosed during childhood. Pediatr Blood Cancer. 2004;42:364–72.
11. CvancarovaM, SamuelsenSO, MagelssenH, FossaSD. Reproduction rates after cancer treatment: experience from the Norwegian radium hospital. J Clin Oncol. 2009;27:334–43.
12. GreenDM, SklarCA, BoiceJD Jr, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2374–81.
13. GreenDM, KawashimaT, StovallM, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2009;27:2677–85.
14. GreenDM, KawashimaT, StovallM, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:332–9.
15. BenArush MW, SoltI, LightmanA, LightmanA, LinnS, KutenA. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2000;17:239–45.
16. ChemaitillyW, MertensAC, MitbyP, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91:1723–8.
17. BehringerK, BreuerK, ReinekeT, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;23:7555–64.
18. van der KaaijMA, HeutteN, Le StangN, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:2825–32.
19. SieniawskiM, ReinekeT, NogovaL, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111:71–6.
20. van den BergH, FurstnerF, van den BosC, BehrendtH. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer. 2004;42:210–5.
21. KiserudCE, FossaA, HolteH, FossaSD. Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer. 2007;96:1442–9.
22. ElisA, TevetA, YerushalmiR, et al. Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:623–7.
23. WatsonM, WheatleyK, HarrisonGA, et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer. 1999;86:1231–9.
24. LeungW, HudsonMM, StricklandDK, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol. 2000;18:3273–9.
25. AnseriniP, ChiodiS, SpinelliS, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant. 2002;30:447–51.
26. CarterA, RobisonLL, FranciscoL, et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant. 2006;37:1023–9.
27. ChengYC, SalibaRM, RondónG, et al. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica. 2005;90:1725–6.
28. SandersJE, HawleyJ, LevyW, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87:3045–52.
29. SaloojaN, SzydloRM, SocieG, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001;358:271–6.
30. SonmezerM, OktayK. Fertility preservation in female patients. Hum Reprod Update. 2004;10:251–66.
31. HickeyM, PeateM, SaundersCM, FriedlanderM. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update. 2009;15:323–39.
32. Pérez-FidalgoJA, RosellóS, García-GarréE, et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat. 2010;120:245–51.
33. FarthingA. Conserving fertility in the management of gynaecological cancers. BJOG. 2006;113:129–34.
34. GershensonDM. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr. 2005;34:43–7.
35. HuygheE, MatsudaT, DaudinM, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer. 2004;100:732–7.
36. MatosE, SkrbincB, ZakotnikB. Fertility in patients treated for testicular cancer. J Cancer Surviv. 2010;4:274–8.
37. HensleyM, FordJM. Imatinib treatment: specific issues related to safety, fertility and pregnancy. Semin Hematol. 2003;40:21–5.
38. ChristopoulosC, DimakopoulouV, RotasE. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med. 2008;358:1079–80.
39. CortesJ, O'BrienS, AultP, et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood. 2008;112: abstract 3230.
40. LeeSJ, SchoverLR, PartridgeAH, et al. American Society of Clinical Oncology. Recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–31.
41. BrusamolinoE, BacigalupoA, BarosiG, et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica. 2009;94:550–65.
42. GrundyR, GosdenRG, HewittM, et al. Fertility preservation for children treated for cancer (1): scientific advances and research dilemmas. Arch Dis Child. 2001;84:355–9.
43. GrundyR, LarcherV, GosdenRG, et al. Fertility preservation for children treated for cancer (2): ethics of consent for gamete storage and experimentation. Arch Dis Child. 2001;84:360–2.
44. HourvitzA, GoldschlagDE, DavisOK, GosdenLV, PalermoGD, RosenwaksZ. Intracytoplasmic sperm injection (ICSI) using cryopreserved sperm from men with malignant neoplasm yields high pregnancy rates. Fertil Steril. 2008;90:557–63.
45. WynsC, CurabaM, VanabelleB, Van LangendoncktA, DonnezJ. Options for fertility preservation in prepubertal boys. Hum Reprod Update. 2010;16:312–28.
46. MeistrichML, ShettyG. Hormonal suppression for fertility preservation in males and females. Reproduction. 2008;136:691–701.
47. GrifoJA, NoyesN. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2010;93:391–6.
48. DonnezJ, JadoulP, SquiffletJ, et al. Ovarian tissue cryopreservation and transplantation in cancer patients. Best Pract Res Clin Obstet Gynaecol. 2010;24:87–100.
49. JadoulP, DolmansMM, DonnezJ. Fertility preservation in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed?Hum Reprod Update. 2010;16:617–30.
50. DolmansMM, MarinescuC, SaussoyP, Van LangendoncktA, AmorimC, DonnezJ. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116:2908–14.
51. MeirowD, HardanI, DorJ, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod. 2008;23:1007–13.
52. OktayK, BuyukE, LibertellaN, AkarM, RosenwaksZ. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23:4347–53.
53. Beck-FruchterR, WeissA, ShalevE. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update. 2007;14:553–61.
Cancel
Confirm
×